Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Coronary Artery Bypass

In brief

This is a randomized-controlled clinical trial that will randomize 120 patients undergoing clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose of 10 mg daily or matching placebo for 12 months, starting at the time of hospital dismissal from surgery. The primary goal of the study is to determine whether prasugrel administration will prevent thrombus (clot) formation within a saphenous vein graft at 12 months, as examined by optical coherence tomography.

Key facts

Study ID
NCT01560780
Run by
VA Office of Research and Development
People needed
84
Starts
2013-02-01
Expected to finish
2018-05-31
Last updated by the study team
2019-10-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.